BMC Biotechnology is currently accepting submissions to a thematic series entitled ' Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy'.
Chimeric antigen receptor (CAR) T cells therapies, as a novel modality in cancer immunotherapy, provide a quantum leap in the treatment of cancer. In recognition of the new advances that the CAR approach represents in hematological malignancies, the Food and Drug Administration (FDA) recently approved two separate cell-based gene therapies, one from Novartis (Kamryah) the other from Gilead (Yescarta) for treatment of B cell leukemias. These concrete steps that advance the CAR therapy into the clinic provide the backdrop and motivation to develop new and improved methods for future applications of the CAR immunotherapy. We envision that research into viral vector design, CAR functional domain engineering, antibody targeting to new cancer targets, the selection, growth and metabolic regulation of primary T cells, and the identification of optimal conditions for the culture the engineered T cells prior to the administration to patients will remain the focus of scientific investigations. As such, manuscripts dealing with any of these related topics fit within the scope of this new thematic series.
BMC Biotechnology, in collaboration with BMC Cancer, have agreed to jointly host the thematic series. To present the recent advances in the theory and development of CAR immunotherapy, we invite you and/or members of your research team to submit manuscript(s) for this thematic series.
We are seeking submissions of original research articles (including systematic reviews and meta-analyses), but also commentary articles. This collection will also include invited reviews.
We would welcome direct submission of any original research you would like to be considered. Please submit directly to BMC Cancer or BMC Biotechnology stating in your cover letter that you are targeting the 'CAR Immunotherapy' collection
Deadline for submission to the collection: 31st December 2018.
